MAPT and Alzheimer disease: Nevertheless, FDG-PET can provide a more detailed diagnosis of brain cognitive metabolism and synaptic dysfunction by quantifying toxic Aβ and tau proteins in the brains of AD patients, which drive healthy neurons into the diseased state [60,61,62].